Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti
{"title":"Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.","authors":"Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti","doi":"10.1080/1750743X.2024.2385881","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.<b>Materials and methods:</b> A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.<b>Results:</b> There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.<b>Conclusion:</b> There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2385881","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.Materials and methods: A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.
期刊介绍:
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.
Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.